Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proli...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
EyePoint Pharmaceuticals, Inc.
NCT05383209 · Nonproliferative Diabetic Retinopathy
NCT02718326 · Nonproliferative Diabetic Retinopathy
NCT02834663 · Nonproliferative Diabetic Retinopathy
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Retinal Research Institute
Phoenix, Arizona
Retina Institute of California
Arcadia, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions